Back to Screener

Drugs Made In America Acquisition Corp. Units (DMAAU)

Price$10.69
Growth ScoreC
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-5.12%
Price vs S&P 500 (4W)0.10%
VGM Score56.61
Market Capitalization$257.58M
P/E Ratio (Annual)43.36x

All Metrics

Book Value / Share (Quarterly)$6.96
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)-5.34%
EPS (TTM)$0.22
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$0.22
EPS (Annual)$0.14
ROI (Annual)2.55%
Cash / Share (Quarterly)$0.00
P/E Basic Excl Extra (TTM)38.70x
P/E Normalized (Annual)43.36x
ROA (Last FY)2.48%
EBITD / Share (TTM)$-0.06
Cash Flow / Share (Annual)$-0.02
P/B Ratio1.10x
P/B Ratio (Quarterly)1.50x
ROA (TTM)2.79%
EPS Growth QoQ (YoY)3.63%
EPS Incl Extra (Annual)$0.14
Current Ratio (Annual)0.03x
Quick Ratio (Quarterly)0.03x
3-Month Avg Trading Volume0.12M
P/E Incl Extra (TTM)38.70x
52-Week High$10.62
EPS Excl Extra (Annual)$0.14
26-Week Price Return2.81%
Quick Ratio (Annual)0.02x
13-Week Price Return1.53%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.03x
Enterprise Value$257.66M
Cash / Share (Annual)$0.00
3-Month Return Std Dev2.40%
ROE (Last FY)2.55%
EPS Basic Excl Extra (Annual)$0.14
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.22
ROI (TTM)2.88%
Revenue / Share (Annual)$0.00
P/E Ratio (TTM)38.70x
Year-to-Date Return2.27%
5-Day Price Return0.09%
EPS Normalized (Annual)$0.14
Month-to-Date Return0.00%
EBITD / Share (Annual)$-0.07
P/E Excl Extra (TTM)38.70x
EPS Basic Excl Extra (TTM)$0.22
P/B Ratio (Annual)1.49x
Book Value / Share (Annual)$6.90
Price vs S&P 500 (13W)-6.72%
Beta-0.00x
Revenue / Share (TTM)$0.00
ROE (TTM)2.88%
52-Week Low$10.13
gGradeC
mGradeC
vgmGradeC
Show chart for

Industry Peers — Blank Checks / SPACs(773)

About

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify, acquire, and operate a business in the pharmaceutical or healthcare sector. The company seeks to combine with a domestic drug manufacturer or related healthcare enterprise through a merger or acquisition. It provides investors with exposure to the U.S. pharmaceutical industry through a structured business combination transaction.